Latest PEGylation Stories
-- 3SBio's pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory
SAN FRANCISCO, May 16, 2014 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) is scheduled to present at the upcoming UBS 2014 Global Healthcare Conference in New York at the Sheraton New
SAN FRANCISCO, May 1, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2014 on Wednesday, May 7, 2014, after
Polaris Group Scientific Colleagues from Several University Cancer Centers Present Data at 2014 AACR Meeting in San Diego, CA SAN DIEGO, April 29, 2014 /PRNewswire/ -- Polaris Group
SAN DIEGO, April 2, 2014 /PRNewswire/ -- Polaris Group announced today that Shaw T. Chen, M.D., Ph.D. has joined Polaris Pharmaceuticals, Inc.
MOSCOW, April 2, 2014 /PRNewswire/ -- Hepatera Ltd.
SAN FRANCISCO, Feb.
- The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A WHIPPANY, N.J., Feb.
ResearchMoz include new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019 - Industry Size, Shares, Growth, Trends and Forecast 2019" to its huge collection
SAN FRANCISCO, Jan. 8, 2014 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W.
- The practice of two or more parties jointly purchasing all or part of a butchered cow and dividing the meat between them.